Scientist studying aging reversal and gut-brain axis connections in a modern biomedical laboratory
| |

Zombie Cell Inflammation: How Mitochondria Switch On the SASP

Most public conversation about cellular aging has been about removal. Senescent cells, the "zombie" cells that stop dividing but refuse to die, pile up in tissues as we get older, and for a decade the leading idea has been to find drugs that kill them. A study published in Nature on July 29, 2026 (DOI 10.1038/s41586-026-10791-2), by teams at Mayo Clinic and Sanford Burnham Prebys Medical Discovery Institute takes a different route. It asks what makes these cells harmful in the first place, finds that the answer runs through the mitochondria, and shows that cutting one metabolic supply line calmed inflammation and improved healthspan in aged mice without eliminating a single senescent cell.

Presented By Our Partners

This deep dive walks through what the paper found, how it connects to earlier work on leaky mitochondria and to a drug class already used in cardiology, and, just as important, how far the evidence actually goes today. The short version: this is a strong mechanistic result in cells and mice. There is no human trial of this strategy, and nothing here is a reason to buy a supplement.

Why senescent cells matter, and why killing them is not the only option

Cellular senescence is a stable state of growth arrest triggered by stresses such as DNA damage, oncogene activation, radiation, or simply many rounds of cell division. It is not purely bad. The authors of the Nature paper note that senescence plays roles in embryonic development, tumor suppression, and tissue repair. A damaged cell that stops dividing cannot become a tumor, and a brief burst of senescent signaling helps wounds heal.

The trouble starts when senescent cells linger. They secrete a mixture of cytokines, chemokines, growth factors, and proteases known as the senescence-associated secretory phenotype, or SASP. Persistent SASP is thought to feed the chronic, low-grade inflammation often called inflammaging, and to contribute to frailty, cardiovascular disease, neurodegeneration, and other disorders of aging.

The first generation of responses was senolytic, meaning drugs that selectively kill senescent cells. Darren Baker and colleagues showed in Nature in 2011 (PMID 22048312) that genetically clearing p16-positive cells delayed age-related disorders in a progeroid mouse model. Ming Xu, James Kirkland, and colleagues reported in Nature Medicine in 2018 (PMID 29988130) that the combination of dasatinib and quercetin improved physical function and extended survival in old mice. Human translation has been slower. Unity Biotechnology’s senolytic candidate UBX0101 missed its primary endpoint in a Phase 2 knee osteoarthritis trial in 2020, a reminder that killing cells your tissues partly depend on is a blunt instrument.

That is the context for the senomorphic idea: leave the cells where they are, but turn down the inflammatory program. João Passos, the Mayo Clinic physiologist who is senior author of the new paper, has described his group’s strategy as asking whether the inflammation that makes senescent cells harmful can be switched off, rather than whether the cells can be removed. To do that, you first have to know exactly what switches the program on.

What the Nature paper found

The paper, titled "Mitochondrial metabolism and epigenetic crosstalk drive SASP" (Martini H, Birch J, Marques FDM, Victorelli S, and colleagues; Nature 2026;656:980), was led by first author Hélène Martini in the Passos laboratory, with Peter Adams of Sanford Burnham Prebys as co-corresponding author. Earlier versions of the work circulated as a preprint in December 2024, which is useful because the preprint text describes the experiments in more detail than press coverage does.

Mitochondria control which inflammatory genes are open

The team started with a simple question: how much do mitochondria contribute to the epigenetic state of a senescent cell? Using a system they had previously developed to generate cells that lack mitochondria, they compared senescent cells with and without their mitochondrial network. RNA sequencing identified 53 SASP genes that were upregulated in senescent cells and fell when mitochondria were cleared.

They then examined nine published ChIP-seq datasets spanning senescence induced by radiation, the chemotherapy drug etoposide, oncogene activation, and replicative exhaustion. In mitochondria-depleted senescent cells, histone acetylation at SASP genes, specifically the H3K27ac mark, was reduced. Histone acetylation loosens the packaging of DNA around histone proteins and makes genes easier to transcribe. The implication is that senescent mitochondria are not just bystanders that leak damage signals. They actively keep inflammatory genes accessible.

The pyruvate, citrate, acetyl-CoA route

Histone acetylation needs a raw material: acetyl-CoA, the obligate donor of acetyl groups. Cells can make acetyl-CoA in several ways, but the paper reports that in senescent cells the mitochondrial pyruvate to citrate to acetyl-CoA axis is upregulated, and that mitochondria are a dominant source of the acetyl-CoA used for chromatin modification.

The route works like a supply chain. Pyruvate enters the mitochondria through the mitochondrial pyruvate carrier. Inside, it is converted along the way to citrate. Citrate is exported to the cytoplasm by a transporter called SLC25A1, and there the enzyme ATP-citrate lyase, known as ACLY, cleaves it to release acetyl-CoA, which can then reach the nucleus and be used for histone acetylation. The preprint reported that components of this chain are elevated in senescent cells, that inhibiting the pyruvate carrier lowered many secreted SASP factors, and that SLC25A1 and ACLY were critical for the process. Raising acetyl-CoA levels did the opposite and promoted SASP gene expression.

Two independent signals have to meet

The most interesting part of the paper is that the metabolic signal is necessary but not sufficient. For years, Passos’s group has studied a different mitochondrial route to inflammation: damaged mitochondria leak their own DNA into the cytoplasm, which activates innate immune sensing through the cGAS and STING pathway. The new work identifies the acetyl-CoA route as a second, independent requirement.

Peter Adams summarized the logic as two converging pathways. One changes how DNA is packaged so that SASP genes become accessible, and the other, immune signaling from leaked mitochondrial material, activates the transcription factors that then switch those exposed genes on. In practical terms, acetyl-CoA opens the chromatin so the genes can be read, and the immune signals supply the transcription factors that read them. Remove either and robust SASP expression fails.

What happened when the route was blocked

The researchers used CTPI-2, a small molecule that inhibits SLC25A1, to cut the citrate export step. In senescent cells this reduced histone acetylation at SASP gene locations and limited expression of the program, even though the immune signals from leaky mitochondria were still present. Critically, the treatment suppressed the inflammatory output without reversing the senescent state itself. Cells stayed arrested. They just stopped shouting.

In aged mice, SLC25A1 inhibition reduced chromatin accessibility at SASP loci, dampened inflammation across multiple tissues, and improved tissue function and healthspan, according to the authors and the institutional summaries of the paper. That is the sentence that drove most of the headlines, and it deserves to be read carefully, which is the subject of the limits section below.

A growing body of work points at the same pathway

One reason the finding is credible is that it did not arrive in isolation. Several groups have been circling mitochondria, acetyl-CoA, and SASP from different angles.

Mitochondrial RNA leakage. In a 2025 paper in Nature Communications (PMID 41398033, DOI 10.1038/s41467-025-66159-z; Victorelli S, Eppard M, Martini H, and colleagues, with Passos as senior author), the Mayo group showed that mitochondrial RNA, not just DNA, accumulates in the cytoplasm of senescent cells. It activates the RNA sensors RIG-I and MDA5, leading to aggregation of the adaptor protein MAVS and induction of SASP. The proteins BAX and BAK, better known for their role in cell death, were key to the leak, and deleting them diminished SASP expression in cells and in a mouse model of metabolic dysfunction-associated steatohepatitis, the condition formerly called NASH. Together with the cGAS and STING work, this describes the "immune signal" half of the two-signal model.

ACLY and BRD4. In 2024, a research group at Kumamoto University reported that ACLY is essential for the proinflammatory SASP independent of growth arrest, that citrate-derived acetyl-CoA supports SASP gene enhancers, and that ACLY-dependent enhancers recruit the chromatin reader BRD4. Inhibiting the ACLY and BRD4 axis suppressed inflammatory signaling in senescent cells and in aged mice. That is a separate laboratory arriving at the same metabolic bottleneck from the chromatin side.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Heterogeneity across senescence types. A 2025 study in Redox Biology (PMID 40158257, DOI 10.1016/j.redox.2025.103606) by Inés Marmisolle, Celia Quijano, and colleagues at the Universidad de la República in Uruguay compared mitochondrial metabolism in human fibroblasts made senescent by hydrogen peroxide, doxorubicin, serial passaging, or the H-RAS oncogene. Mitochondrial behavior differed sharply by inducer. Oncogene-induced senescent cells showed higher respiration, and enzymes of acetyl-CoA metabolism shifted, including increased activation of ACLY. Inhibiting ACLY reduced histone H3 acetylation and secretion of SASP components in that model, and the authors identified AMPK and ACLY as potential targets for SASP modulation. The takeaway is both encouraging and cautionary: the pathway shows up repeatedly, but senescence is not one state, and a drug that works in one context may be weaker in another.

The cardiology connection: ACLY is already a drug target

Here the story takes a turn that is particularly relevant for readers following cardiovascular health. ACLY is not a hypothetical target. Bempedoic acid, approved by the US Food and Drug Administration in 2020, is an oral ACLY inhibitor used to lower LDL cholesterol.

The mechanism is elegant. Bempedoic acid is a prodrug. It must be converted into its active form by an enzyme called very-long-chain acyl-CoA synthetase 1, or ACSVL1, which is abundant in the liver and largely absent from skeletal muscle. That restricts ACLY inhibition mainly to the liver, which lowers cholesterol synthesis one step upstream of where statins act and avoids much of the muscle toxicity that leads some patients to stop statins.

The cardiovascular outcomes evidence is substantial. In the CLEAR Outcomes trial (Nissen SE and colleagues, New England Journal of Medicine 2023), roughly 14,000 high-risk patients who were unable or unwilling to take statins were randomized to bempedoic acid 180 mg or placebo and followed for a mean of about 40 months. Bempedoic acid reduced the four-component composite of major adverse cardiovascular events by about 13 percent in relative terms. LDL cholesterol fell by about 21 percent, and levels of C-reactive protein, a marker of inflammation, also fell. The side effect profile included more hyperuricemia (about 10.9 percent versus 5.6 percent with placebo), slightly more gout (3.1 percent versus 2.1 percent), more gallstones (about 2.2 percent versus 1.2 percent), and more liver enzyme elevations above three times the upper limit of normal (4.5 percent versus 3 percent).

It is tempting to connect the dots and say that blocking ACLY calms senescent cell inflammation and therefore protects hearts. That would be a leap. The CLEAR Outcomes benefit is well explained by LDL lowering, and the trial was not designed to test anti-SASP effects. Because bempedoic acid is activated mainly in liver and kidney tissue, it is also unlikely to deliver ACLY inhibition to the senescent cells scattered through other organs. What the connection does show is that the enzyme at the heart of this pathway can be drugged safely in people, at least in the liver, over years. For drug developers, that is a meaningful piece of de-risking, even though the mouse study targeted a different node, the SLC25A1 transporter.

Why the senomorphic approach is attractive, and what could go wrong

If senescent cells can be quieted rather than killed, several advantages follow in theory. Senescent cells that suppress tumors or aid wound repair stay in place. There is no sudden release of cellular debris from mass cell death. Dosing could in principle be adjusted to dial inflammation down rather than eliminate a cell population.

But the approach carries its own risks, and the paper’s biology hints at several.

Acetyl-CoA is not only an aging molecule. Every cell uses acetyl-CoA for fatty acid synthesis, protein acetylation, and energy metabolism. A drug that limits its supply risks effects in healthy tissues, especially rapidly dividing ones and the brain. The mouse results suggest a tolerable window exists in that experiment, but chronic treatment over a human lifespan is another matter.

SLC25A1 matters in humans. Inherited loss of SLC25A1 function causes a rare and serious neurometabolic disorder, which tells us this transporter does essential work. Partial, drug-based inhibition is very different from complete genetic loss, but it is a reason for caution about whole-body, long-term blockade.

Silenced senescent cells are still senescent cells. Because CTPI-2 does not clear them, they remain in tissue. If their harmful effects include non-SASP mechanisms, such as altered tissue structure or impaired stem cell niches, quieting inflammation alone may only deliver part of the benefit, and the cells could be a lasting liability.

Immunity and wound healing. SASP has genuine functions in recruiting immune cells to clear damaged or precancerous cells. Dampening it chronically could, in principle, blunt those surveillance functions. The paper did not report this, and it deserves explicit study in aged animals challenged with infection or tumors.

What the evidence does and does not show

Reading the Nature paper for what it is, the evidence breaks down this way.

Strong, well-replicated: Mitochondrial metabolism influences SASP gene expression in senescent cells. The pyruvate, citrate, and acetyl-CoA route is elevated in senescence and feeds histone acetylation at SASP genes. Independent groups, including the Kumamoto team and the Uruguayan team, reached overlapping conclusions about ACLY.

Promising, early: Blocking SLC25A1 with CTPI-2 reduced inflammation and improved healthspan in aged mice. This is the single result most likely to be overinterpreted. Mouse healthspan measures vary in quality, results in short-lived laboratory mice often fail to translate to people, and the paper reports benefits for the strategy but not a human safety profile. Any sample sizes, sexes, doses, and exact functional endpoints should be checked in the full paper before drawing conclusions about the magnitude of benefit.

Unproven: That any drug targeting this pathway will lower inflammaging in humans, reduce frailty, or extend healthspan. No human trial of SLC25A1 inhibition for aging exists. CTPI-2 is a research compound, not a medicine.

It is also worth noting that this paper is part of a broader pattern in aging biology: the most durable advances tend to come from identifying a precise mechanism first and then asking whether it can be drugged, rather than starting from a supplement and working backward. The preprint’s abstract frames the work exactly that way, calling mitochondrial metabolism pivotal to the epigenetic control of aging, a claim that is mechanistic rather than clinical.

What to watch next

Several developments would move this field from interesting to actionable.

First, replication and extension in other models, including different aged mouse strains, both sexes, and tissues beyond those profiled. Second, a safety and tolerability picture for chronic SLC25A1 or ACLY inhibition outside the liver. Third, biomarkers that let researchers measure SASP in living people, since a trial needs a way to show the inflammatory program actually changed. Fourth, comparisons or combinations with senolytics, since a senomorphic drug and a senolytic might be complementary: one to quiet the cells that remain, the other to clear the ones that have become irreversibly harmful.

For now, the most reliable human data on this pathway come from the cholesterol field, not from aging research.

What This Means For You

If you came here wondering whether you should do something differently after reading about this study, the honest answer is that nothing about your routine needs to change because of it. But there are useful, grounded takeaways.

Do not buy "acetyl-CoA blockers" or mitochondrial citrate supplements. No such product has been shown to do what the mouse study did, and the biology says acetyl-CoA is essential, so blocking it indiscriminately is not obviously safe. CTPI-2 is not for sale as a medicine, and anything marketed on the strength of this paper is running ahead of the evidence.

Do not treat bempedoic acid as an anti-aging drug. It is a prescription LDL-lowering medication with a specific, evidence-based role, mainly in people who cannot tolerate statins and who are at high cardiovascular risk. It carries real side effects, including gout and gallstone risk. Whether it affects senescent cell inflammation in people is untested. If your cholesterol is a concern, that is a conversation for your doctor, based on your LDL, your history, and your risk, not on this paper.

Focus on the inflammation levers with human evidence. The best-supported ways to lower chronic inflammation in people are not exotic: regular physical activity, adequate sleep, not smoking, avoiding excess visceral fat, and managing blood pressure, blood sugar, and cholesterol. These affect the same inflammatory tone the senescence field is trying to target, and they have outcome data behind them that no senomorphic drug yet has.

Ask about inflammation markers in context. A high-sensitivity C-reactive protein test is a common, inexpensive measure of systemic inflammation. It is not a test for senescent cells, and a single reading can be affected by recent illness, but it is a reasonable item to discuss with a clinician if you have cardiovascular risk factors.

Watch for trials, not headlines. If this pathway matures, the signal to look for is a registered human trial with a defined inflammatory biomarker or functional endpoint, not another mouse paper and not a supplement label. Healthcare Discovery will track those developments as they arrive.

The larger lesson of the study is conceptual. For years, aging biology treated senescent cells as targets to be destroyed. This work argues that the real problem is a specific, metabolically dependent inflammatory program, and that programs can in principle be tuned. Whether that tuning ever becomes a safe medicine is an open question, but it is now a much better defined one.

Frequently asked questions

What is the SASP? The senescence-associated secretory phenotype is the mix of inflammatory proteins that senescent cells release. It can be useful briefly and harmful when chronic.

What is a senomorphic? A senomorphic is a drug that suppresses the harmful secretions of senescent cells without killing them, as opposed to a senolytic, which kills them.

Was this tested in humans? No. The key findings come from cultured cells and aged mice. No human trial of SLC25A1 inhibition for aging exists.

Is bempedoic acid the same thing as the drug in the study? No. Bempedoic acid inhibits ACLY, which sits one step downstream of the SLC25A1 transporter the study targeted. The two are related by pathway, not interchangeable.

Sources and further reading

  • Martini H, Birch J, Marques FDM, Victorelli S, and colleagues. Mitochondrial metabolism and epigenetic crosstalk drive SASP. Nature. 2026;656:980. DOI 10.1038/s41586-026-10791-2. Preprint: Research Square, December 2024 (PMID 39678326).
  • Victorelli S, Eppard M, Martini H, and colleagues. Mitochondrial RNA cytosolic leakage drives the SASP. Nature Communications. 2025;16:10992. DOI 10.1038/s41467-025-66159-z (PMID 41398033).
  • Marmisolle I, Chacon E, Mansilla S, and colleagues. Oncogene-induced senescence mitochondrial metabolism and bioenergetics drive the secretory phenotype. Redox Biology. 2025;82:103606. DOI 10.1016/j.redox.2025.103606 (PMID 40158257).
  • Nissen SE and colleagues. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients (CLEAR Outcomes). New England Journal of Medicine. 2023.
  • Sanford Burnham Prebys press release, August 20, 2026, and Mayo Clinic summary of the Nature study.
  • Baker DJ and colleagues. Nature. 2011; Xu M and colleagues. Nature Medicine. 2018.

This article is for general education and is not medical advice. Talk with a qualified clinician about your own health decisions.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

No spam. Unsubscribe anytime. We respect your inbox.

Similar Posts